The Gene Dossier a Potted History Fiona Stewart. The Start Was not very promising Quite a lot of hostility to the idea that anyone would consider telling.

Slides:



Advertisements
Similar presentations
MEASURING COST- EFFECTIVENESS AT A LOCAL LEVEL Pamela Meadows National Evaluation of Sure Start Team.
Advertisements

You have to provide a laboratory service for a Caucasian population of 3 million. How would you go about this? Describe your strategy for staff and equipment.
You have recently set up a new disease service in your laboratory. What is the role of the UKGTN? Describe the process involved in submission & evaluation.
Participation Requirements for a Guideline Panel Member.
Research Design Service West Midlands RfPB Research Funding Application Workshop 28 th February 2014.
The Aged Care Standards and Accreditation Agency Ltd Continuous Improvement in Residential Aged Care.
Participation Requirements for a Guideline Panel Co-Chair.
VUS: The clinician’s view Mary Porteous On behalf of Scottish Clinical Geneticists.
Engaging Patients and Other Stakeholders in Clinical Research
Participation Requirements for a Patient Representative.
Relieving distress, transforming lives Data Collection in IAPT The Importance of collecting data in IAPT-compliant services (References: The IAPT Data.
Student Job Centre 2012 Student Job Centre Sault College Career Essentials Mentors.
Care and support and you. Care Act – national campaign Radio adverts on Smooth, Gold, Magic from 2 February Leaflets posted through doors in Swinton and.
Participation Requirements for a Guideline Panel PGIN Representative.
Faculty Dan O’Connell, Ph.D. To reach Dan:
Does It Work? Evaluating Your Program
ACMG Recommendation: All laboratories conducting clinical sequencing should seek and report expected pathogenic mutations for a short list of carefully.
Church Road Surgery Patient Feedback Questionnaire August 2013.
Why Are We Here? The History and Landscape of DTC Genetic Tests Elizabeth Mansfield, Ph.D. OIVD/CDRH/FDA March 8, 2011 Molecular and Clinical Genetics.
I inherited What??? You and Your Genes: The Explosive New World of Genetics David Finegold, M.D.
Role of clinical genetics in medicine. Who provides this service Varies depending on structure and funding of service but is in reality provided by many.
Affymetrix Resequencing Arrays Matthew Smith Trainee Presentation West Midlands Regional Genetics Laboratory.
Jacquie Westwood UK Genetic Testing Network.  Approving UKGTN member labs who provide quality assured tests  Acknowledgment – UKGTN Laboratory Membership.
Meta-cognition Rhiannon, Niall, Heather, Frances.
Criteria and Standard.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Creating a service Idea. Creating a service Networking / consultation Identify the need Find funding Create a project plan Business Plan.
Practical Placements & the QAA and ASET Guidelines By Ian Sunley & Lorna Uden Faculty of Computing, Engineering & Technology, Staffordshire University,
Getting in on the Act : The 2014 SEND Reforms Explained Jane Friswell Chief Executive.
Sampling. Concerns 1)Representativeness of the Sample: Does the sample accurately portray the population from which it is drawn 2)Time and Change: Was.
Appraisal Review September What is an Appraisal Review This is the evaluation process between you and your line manager that reviews your work over.
PATIENT SURVEY ACTION PLAN We now have an active Patient Participation Group! The priorities for this plan have been discussed and agreed together.
Role of Consumers U.S. Health Care System. Perfect competition assumes consumers and producers have perfect information. What’s so good about perfect.
Judy Dean Managing Director Tips in Addressing Carrier Medical Directors.
The work of the Research Ethics Committee Dr Carol Chu.
LESSON 9.5: TYPES OF STUDIES Module 9: Epidemiology Obj. 9.5: Compare & contrast different types of epidemiological studies.
Learning From Patients Engaging Patients in Primary Care Tanya Lord, PhD 1.
Marfan’s syndrome and related aortopathies Shehla Mohammed.
1 SCREENING. 2 Why screen? Who wants to screen? n Doctors n Labs n Hospitals n Drug companies n Public n Who doesn’t ?
How to do a good presentation ALI B ALHAILIY. A- Planning the Presentation 1- Write note cards on index cards. Write main ideas on your index cards. Don't.
A–Level Computing Project Introduction. Learning objectives Become familiar with the: Guidelines associated with choosing a project. Stages in project.
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.
BHIVA PROMS / PREMS PROJECT A Community Consultation.
Human Genetics and Genetic Technology Using Genetic InformationUsing Genetic Information.
Integrated systems of care Presented by: Jolanta McCall Head of Paediatric Audiology/NHSP.
Understanding Genetic Testing
Integration of Bioinformatics into Inquiry Based Learning by Kathleen Gabric.
NIHR Themed Call Prevention and treatment of obesity Writing a good application and the role of the RDS 19 th January 2016.
Ethics in Clinical Genetics and Genomics Key Knowledge Year 4 Medical Ethics and Law Thread Course, The Ethox Centre, University of Oxford.
Genetic testing and the United Kingdom Genetic Testing Network Professor Peter Farndon Chair UKGTN Presentation with images removed.
Presented by The Solutions Group Decision Making Tools.
Uterovaginal Prolapse
Surrey Heath Clinical Commissioning Group
Genetic Testing in Human: The Clinician’s Perspective ncbi
Time Series Consistency
Uterovaginal Prolapse
Deer Park Family Medical Practice Questionnaire
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Hernia Local commissioners working with local people for a healthier.
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Knee Replacement Local commissioners working with local people for a.
Clinical practice guidelines and Clinical audit
Scenario 25: Peer mentoring
The NICE Citizens Council and the role of social value judgements
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
Newborn screening and the future – Where do we go from here?
Targeting Positioning
EDUC 5139 School Finance and Campus Budgeting Principal interview
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Correction of Ptosis Local commissioners working with local people for.
Genetic Testing for RP. Case Study of the UK
Levels of involvement Consultation Collaboration User control
Presentation transcript:

The Gene Dossier a Potted History Fiona Stewart

The Start Was not very promising Quite a lot of hostility to the idea that anyone would consider telling clinicians or laboratories who should have genetic tests and in what circumstances

First meeting of the steering group was on September 17 th 2002

Gene Dossier Process Laboratory decides it wishes to offer a test through the UKGTN Gene dossier is down loaded from UKGTN website and completed Gene dossier is submitted to UKGTN and is assessed If approved goes onto the directory

The first gene dossier meeting Involved the whole steering group We were sent 80+ dossiers to consider prior to the meeting

The meeting Probably fair to say there was a general feeling particularly amongst clinicians that if a test could ever be offered to anyone in any circumstances then it should be approved No real feeling that we should define who the test was for and in what circumstances it might be appropriate to offer it (with a few exceptions!) Pretty much all dossiers approved

Changes Realised that it was impractical to have all GDs considered by the entire steering group Better to have a smaller group to consider the dossiers Those that were approved would then go to the steering group for endorsement A sub group was set up initially called the Gene Dossier Group now called the Genetic Test Evaluation Working Group

Composition of GD group At least one of the following: Clinical Geneticist Clinical Scientist Commissioner Public Health Genetic Counsellor Patient Representative UKGTN staff and the UKGTN expert clinical advisors

Single Gene Testing Initially all GDs were for one gene for one condition Target population defined more carefully Clinical indications for the test important What was the clinical usefulness of the test? What did this information add to the overall care and management of the patient and their family

Testing Criteria Realised we had to define the population to whom the test should be offered Also realised that there is a huge pressure on clinicians to offer a wide range of genetic tests to patients and some guidance about who might benefit most from the test would be helpful and might be welcomed by clinicians Might also give some supportive evidence for cases where the clinician feels the test is not indicated Testing criteria were introduced in 2006

Care Pathways Very important to know where the genetic test fits into the investigative pathway In conditions where there may be a number of genetic tests it is helpful to know in which order genes should be tested and what other tests and actions might be indicated We started to ask laboratories to supply testing strategies in some cases

Our priority is to try and make things user friendly for the clinician With the mainstreaming of genetic tests we know that some users will not be as familiar with the area of genetics Therefore we feel testing strategies and testing criteria might be very useful

The Ultra Rares We realised that a lot of time was being spent discussing dossiers for tests which might only be applicable to less than 5 patients per year These tests are now first assessed by the expert advisors and come to the group for endorsement of their decision.

Panel Tests We are receiving an increasing number of panel tests These tests tend to use next generation sequencing and can look at a number of genes at once They are particularly useful for conditions where a number of different genes can give a very similar if not identical clinical picture e.g. Retinitis pigmentosa

Costs Although the cost of the panel test may be higher than a single gene test they may avoid the need for serial genetic testing A good example is hereditary sensory motor neuropathy. If an affected individual does not have the common PMP22 duplication then serial testing of all the other genes, each of which may have a low pick up rate, can be very costly

Advantages to Patients It can be very time consuming to test genes sequentially so an all at once strategy can provide a more rapid result for the patient

Important points Coverage may not be optimal for all the genes so if there is clear indication that a single gene is likely to responsible it is best to test for that first If a mutation is found then family follow up and/or prenatal diagnosis would be done using the single gene test not the panel test

The future..... More panel tests Whole exome sequencing Whole genome sequencing

Principles Right patient Right test Right time These principles hold true whatever methodology is available now or in the future

Special thanks to all the members of the Genetic Testing and Evaluation Working Group who have spent many happy hours pouring over gene dossiers Also thanks to the expert advisors Mark, Su and Shehla who are truly experts and whose input is invaluable Finally thanks to Peta, Jacqui and Jane plus other members of the UKGTN who have provided such great support over the years